Neurology in Delaware

Omniscient Neurotechnology develops AI-powered connectomic analysis software for precision brain mapping and surgical planning. The company specializes in digital brain mapping technology that generates personalized connectomes—computational maps of brain functional and structural connections—using advanced algorithms and cloud-based processing of MRI and resting-state functional MRI (rs-fMRI) data. Quicktome is their flagship platform, an automated connectomic analysis solution designed for neurosurgeons and researchers to extract actionable insights into patient-specific brain networks prior to surgery and for large-scale neural data processing in research settings. The platform supports clinical decision-making across neurologic conditions including cranial surgery, neuro-oncology, depression, Alzheimer's disease, schizophrenia, and stroke. By automating what historically required manual tractography and reducing processing time from hours to under 2 hours with minimal clinician intervention, Quicktome enables faster surgical planning while preserving critical functional brain regions. The company operates through global distribution partnerships and maintains offices in Australia (Sydney, NSW) and the United States (Atlanta). Omniscient holds SOC 2 compliance certification and patents issued by the USPTO. The technology is positioned at the intersection of neuroimaging, artificial intelligence, and cloud computing, serving both clinical and research institutions worldwide.

QuantalX Neuroscience manufactures Delphi-MD™, a non-invasive brain network function assessment device using Direct Electrophysiological Imaging technology to map real-time brain activity. The device captures transcranial magnetic stimulation (TMS)-evoked brain potentials (TEPs) and provides quantitative output parameters compared against a normative reference database for ages 50–75. Unlike conventional neuroimaging, Delphi-MD™ operates in any care setting—clinics, hospitals, research facilities—without radiation exposure. The system is indicated for brain health assessment, neurology, psychiatry, and research applications. FDA De Novo cleared, the device generates comprehensive, age-correlated results reports integrated into clinical workflows. Key features include rapid assessment, radiation-free operation, proven validation through peer-reviewed publications, and cost-effectiveness. Clinical interpretations must be made by qualified healthcare professionals within full patient evaluation context. Potential adverse events include headache, nausea, dizziness, fatigue, insomnia, anxiety, back/neck pain, vomiting, tinnitus, migraine aura, and abnormal sensations. The device is not intended as a sole diagnostic tool. Serves providers, researchers, and institutional buyers seeking objective, accessible brain function measurement.

Brain Navi is a Taiwan-based neurosurgical medical device company specializing in advanced surgical navigation and visualization systems for intracranial procedures. The company manufactures two primary product lines: NaoTrac, an autonomous neurosurgical navigation robot that guides surgeons to target locations following pre-planned surgical pathways, and KrystoLens, a single-use 2D/3D neuro-endoscope with a wide surgical working channel designed for minimally invasive intracranial surgery. NaoTrac achieved FDA clearance in June 2025 and has been deployed at leading neurosurgical centers including Medizinische Universität Lausitz in Germany. The company's mission is to improve surgical accuracy, streamline neurosurgical procedures, and reduce surgeon learning curves. Products are designed for neurosurgeons performing brain and spinal procedures requiring high precision and visualization. Brain Navi serves international markets and participates in major medical conferences and surgical events to demonstrate clinical applications and train surgical teams.

Vistim Labs develops Ceregram, a patented Evoked Potential Tomography (EPT) technology for non-invasive, radiation-free neurological monitoring. The platform is designed to track disease progression in dementia patients (Alzheimer's, Parkinson's, Lewy Body Disease) and other neurological disorders by localizing and quantifying sensory deficits caused by neurodegeneration. Ceregram monitors across multiple disease endpoints including brain volume changes, physiological markers (amyloid and tau accumulation), and psychological/cognitive performance metrics (MMSE, CERAD, TASIT). The technology enables point-of-care evaluation in office-based clinical settings, allowing physicians to assess treatment response and adjust disease management in real time without requiring PET imaging or other advanced neuroimaging. The company has published peer-reviewed research in Alzheimer's Research and Therapy Journal and presented findings at major conferences including the American Academy of Neurology (2025) and Alzheimer's Association International Conference (2023). Ceregram is positioned as a clinical decision-support tool for cognitive monitoring and is not intended as a diagnostic device or replacement for PET, MRI, or other imaging modalities. The company operates with offices in Miami and San Diego, with affiliate locations in New York, Paris, and Berlin. Vistim Labs has participated in biotech accelerators (PharmStars, Boston) and won multiple startup pitch competitions.

Solvemed Inc. develops PuRe™ Pupillometer, a smartphone-based FDA Class I medical device for objective pupillary assessment in critical care settings. The device employs computational pupillometry to measure pupil size and reactivity with superior accuracy across varying ambient light conditions—addressing a key limitation of conventional infrared pupillometers, which show significant measurement variability in different lighting environments. The PuRe™ score is a lighting-invariant metric derived from exposure-corrected pupillary parameters and is openly published for research benefit. The software integrates securely with major hospital EMR systems (Epic, Oracle, Athena, Meditech, Allscripts, eClinicalWorks) via HIPAA-compliant cloud infrastructure with SOC2 certification. The solution eliminates disposable costs and hardware logistics while providing immediate EMR data upload. Clinical collaborations span Emory Healthcare, NHS Oxford, Harvard-affiliated institutions, and UK research centers. Designed for neuro-ICU, medical-ICU, cardiac-ICU, surgical-ICU, trauma centers, stroke units, and emergency departments. No hardware required; operates on iOS devices with Face ID authentication. The device enables standardized, reproducible neurological assessment comparable to automated vital-sign measurement.